Lisa Coussens
#90,590
Most Influential Person Now
Cancer researcher
Lisa Coussens's AcademicInfluence.com Rankings
Lisa Coussenslaw Degrees
Law
#1535
World Rank
#1925
Historical Rank
Common Law
#35
World Rank
#38
Historical Rank
Lisa Coussensbiology Degrees
Biology
#4160
World Rank
#6245
Historical Rank
Immunology
#170
World Rank
#178
Historical Rank
Download Badge
Law Biology
Lisa Coussens's Degrees
- Bachelors Biological Sciences University of California, Irvine
Why Is Lisa Coussens Influential?
(Suggest an Edit or Addition)According to Wikipedia, Lisa M. Coussens is an American cancer scientist who is Chair of the Department of Cell, Developmental and Cancer Biology and Professor and Associate Director for Basic Research in the Knight Cancer Institute at the Oregon Health & Science University. She serves as President of the American Association for Cancer Research.
Lisa Coussens's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Inflammation and cancer (2002) (5987)
- Accessories to the crime: functions of cells recruited to the tumor microenvironment. (2012) (3496)
- Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations (2002) (2687)
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients (2018) (2594)
- Understanding the tumor immune microenvironment (TIME) for effective therapy (2018) (2583)
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells (1984) (2426)
- Paradoxical roles of the immune system during cancer development (2006) (2210)
- Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes (1985) (1886)
- Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. (1985) (1878)
- Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. (1987) (1557)
- Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. (2011) (1476)
- MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis (2000) (1345)
- CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. (2009) (1208)
- Macrophages and therapeutic resistance in cancer. (2015) (1001)
- Tumor stroma and regulation of cancer development. (2006) (1000)
- Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. (1999) (994)
- Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. (2016) (987)
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? (2013) (958)
- Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. (1986) (933)
- De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. (2005) (772)
- The complete primary structure of protein kinase C--the major phorbol ester receptor. (1986) (749)
- Differential macrophage programming in the tumor microenvironment. (2012) (743)
- Cancer: An inflammatory link (2004) (677)
- Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. (2014) (671)
- Macrophages and Metabolism in the Tumor Microenvironment. (2019) (636)
- Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression (2007) (631)
- The Basis of Oncoimmunology (2016) (593)
- Matrix metalloproteinases and the development of cancer. (1996) (574)
- Collagen-based cell migration models in vitro and in vivo. (2009) (565)
- Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. (2010) (536)
- The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. (1985) (533)
- FcRgamma activation regulates inflammation-associated squamous carcinogenesis. (2010) (501)
- Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity (2010) (477)
- Tumor microenvironment complexity: emerging roles in cancer therapy. (2012) (469)
- Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets (2019) (442)
- Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus (1986) (419)
- Leukocyte composition of human breast cancer (2011) (405)
- Humoral immunity, inflammation and cancer. (2007) (399)
- Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy (2018) (382)
- Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression (2007) (376)
- Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. (2017) (364)
- Immune cells as mediators of solid tumor metastasis (2008) (362)
- Classification of current anticancer immunotherapies (2014) (357)
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. (2016) (353)
- Functionally distinct insulin receptors generated by tissue‐specific alternative splicing. (1990) (341)
- The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. (2008) (340)
- Cancer and Inflammation: Promise for Biologic Therapy (2010) (319)
- A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. (1988) (318)
- Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models (2018) (316)
- CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells (2013) (310)
- Immune microenvironments in solid tumors: new targets for therapy. (2011) (307)
- B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis (2011) (290)
- B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. (2014) (243)
- MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles (2011) (236)
- The tumor microenvironment: a critical determinant of neoplastic evolution. (2003) (235)
- Proteases, extracellular matrix, and cancer: a workshop of the path B study section. (2004) (234)
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) (234)
- Lymphocytes in cancer development: polarization towards pro-tumor immunity. (2010) (229)
- The inflammatory tumor microenvironment and its impact on cancer development. (2006) (229)
- Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. (1996) (226)
- Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment (2004) (221)
- Inflammatory Cells and Cancer (2001) (220)
- Inflammatory Cells and Cancer: Think Different! (2001) (214)
- TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. (2018) (200)
- Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells (2003) (191)
- Polarized immune responses differentially regulate cancer development (2008) (189)
- Leukocytes in mammary development and cancer. (2011) (188)
- Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions (2017) (188)
- Inflammation, proteases and cancer. (2006) (179)
- TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy (2015) (174)
- Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival (2018) (174)
- Matrix‐degrading proteases and angiogenesis during development and tumor formation (1999) (173)
- MMP9 potentiates pulmonary metastasis formation. (2002) (158)
- Extrinsic regulators of epithelial tumor progression: metalloproteinases. (2000) (153)
- Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. (2007) (152)
- The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. (2005) (151)
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. (2017) (145)
- Neutralizing tumor-promoting chronic inflammation: A magic bullet? (Science (286)) (2013) (143)
- The Tumor-Immune Microenvironment and Response to Radiation Therapy (2010) (129)
- Topology of signal recognition particle receptor in endoplasmic reticulum membrane (1985) (125)
- A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. (2014) (121)
- Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma (2013) (114)
- Soluble mediators of inflammation during tumor development. (2005) (109)
- RECKing MMP function: implications for cancer development. (2002) (108)
- Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. (2018) (100)
- The human gene for the beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. (1983) (99)
- Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis (2010) (98)
- A Functional Proteomics Screen of Proteases In Colorectal Carcinoma (2000) (97)
- The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer (2019) (96)
- Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. (1998) (95)
- The interplay between innate and adaptive immunity regulates cancer development (2005) (93)
- Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. (2002) (90)
- Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. (2019) (87)
- Stromal regulation of vessel stability by MMP14 and TGFβ (2010) (84)
- Tumor-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression (2020) (81)
- Alternative splicing increases the diversity of the human protein kinase C family. (1987) (81)
- TIMP-1 Alters Susceptibility to Carcinogenesis (2004) (77)
- Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. (2015) (76)
- Cathepsin C is a tissue-specific regulator of squamous carcinogenesis (2013) (72)
- Early detection of cancer (2022) (70)
- B cells and their mediators as targets for therapy in solid tumors. (2013) (67)
- Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors (2019) (63)
- A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. (2006) (62)
- Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. (2016) (62)
- Development of an optimized activatable MMP-14 targeted SPECT imaging probe. (2009) (59)
- Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer (2019) (57)
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (57)
- MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment (2016) (54)
- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer (2020) (54)
- FcR g Activation Regulates Inflammation-Associated Squamous Carcinogenesis (2011) (53)
- Leukocytes as paracrine regulators of metastasis and determinants of organ‐specific colonization (2011) (53)
- MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging (2021) (53)
- Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma (2016) (53)
- Delineating protease functions during cancer development. (2009) (51)
- Early neoplastic progression is complement independent. (2004) (50)
- Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. (2021) (48)
- Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma (2019) (47)
- Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development (2007) (46)
- Senescence and cancer: An evolving inflammatory paradox. (2016) (45)
- IKKα at the Crossroads of Inflammation and Metastasis (2007) (45)
- Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer (2019) (44)
- Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study. (2021) (44)
- Dendritic Cells, Inflammation, and Breast Cancer (2013) (43)
- Growth hormone stimulates insulin gene expression in cultured human fetal pancreatic islets. (1988) (41)
- EMX2 is epigenetically silenced and suppresses growth in human lung cancer (2010) (41)
- Genetic and cellular mechanisms of oncogenesis. (2008) (40)
- Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. (2004) (39)
- High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. (2020) (39)
- Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer (2020) (38)
- Mammary Gland Involution as an Immunotherapeutic Target for Postpartum Breast Cancer (2014) (36)
- Structural gene for beta-nerve growth factor not defective in familial dysautonomia. (1984) (36)
- MR imaging of tumor-associated macrophages (2012) (36)
- Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer (2018) (35)
- Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. (2007) (35)
- Models for gain-of-function and loss-of-function of MMPs. Transgenic and gene targeted mice. (2001) (34)
- Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer (2021) (33)
- Myeloid Cells as Targets for Therapy in Solid Tumors. (2015) (33)
- Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer (2018) (33)
- B cells as biomarkers: predicting immune checkpoint therapy adverse events. (2018) (32)
- AACR Cancer Progress Report 2016 (2016) (32)
- Protective role of cathepsin L in mouse skin carcinogenesis (2012) (31)
- Inflaming gastrointestinal oncogenic programming. (2008) (30)
- Analysis of immune cell infiltrates during squamous carcinoma development. (2006) (30)
- Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. (2010) (26)
- Biology and Regulation of the Matrix Metalloproteinases (2001) (26)
- Immune cells as anti‐cancer therapeutic targets and tools (2007) (25)
- Sequence homology of human and mouse beta-NGF subunit genes. (1983) (24)
- Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment (2022) (23)
- MITI minimum information guidelines for highly multiplexed tissue images (2021) (22)
- Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. (2019) (21)
- Duality of the immune response in cancer: lessons learned from skin. (2014) (21)
- Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis. (2016) (21)
- TH 2-Polarized CD 4 þ T Cells and Macrophages Limit Ef fi cacy of Radiotherapy (2015) (20)
- Hu/Mu ProtIn Oligonucleotide Microarray: Dual-Species Array for Profiling Protease and Protease Inhibitor Gene Expression in Tumors and Their Microenvironment (2007) (20)
- Protein kinases in cellular signal transduction: tyrosine kinase growth factor receptors and protein kinase C. (1986) (19)
- Sustained Endothelial Expression of HoxA5 In Vivo Impairs Pathological Angiogenesis And Tumor Progression (2015) (19)
- IKKalpha at the crossroads of inflammation and metastasis. (2007) (19)
- Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers (2019) (18)
- Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis (2008) (18)
- Transforming growth factor β1‐mediated induction of junB is selectively inhibited by expression of Ad.12‐E1A (1994) (17)
- Innate αβ T cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. (2019) (17)
- Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. (2019) (16)
- Histamine restricts cancer: nothing to sneeze at (2011) (16)
- Unimpeded skin carcinogenesis in K14‐HPV16 transgenic mice deficient for plasminogen activator inhibitor (2011) (15)
- CRS‐207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial: 208O_PR (2016) (14)
- Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status (2019) (14)
- Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity (2019) (14)
- High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer (2021) (13)
- Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma (2022) (12)
- Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. (2016) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Structure of human epidermal growth factor receptor and expression of normal and variant mRNAs in epidermoid carcinoma cells (1985) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). (2016) (10)
- EMX2 is epigenetically silenced and suppresses growth in human lung cancer (2010) (10)
- Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer (2017) (9)
- A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. (2014) (9)
- A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs (2022) (9)
- An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer (2020) (9)
- Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies (2021) (8)
- A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE). (2016) (8)
- Three‐Dimensional Visualization of Blood and Lymphatic Vasculature in Tissue Whole Mounts Using Confocal Microscopy (2005) (7)
- Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer (2019) (7)
- Multiplexed immunohistochemistry image analysis using sparse coding (2017) (7)
- Inflammation promotes tumor aggression by stimulating stromal cell-dependent collagen crosslinking and stromal stiffening (2020) (6)
- Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma (2021) (6)
- Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC (2021) (6)
- Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study (2021) (6)
- A Cancer Cell–Intrinsic GOT2–PPARδ Axis Suppresses Antitumor Immunity (2020) (6)
- Macrophage Expression of HIF-1 α Suppresses T cell Function and Promotes Tumor Progression (2010) (6)
- Manipulating microRNAs to regulate macrophage polarization in gliomas. (2014) (5)
- To Help or To Harm (2018) (5)
- 447PDPHASE IB STUDY OF PLX3397, A CSF1R INHIBITOR, AND PACLITAXEL IN PATIENTS WITH ADVANCED SOLID TUMORS. (2014) (5)
- Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer. (2021) (5)
- Single-Cell Spatial Proteomics Analyses of Head and Neck Squamous Cell Carcinoma Reveal Tumor Heterogeneity and Immune Architectures Associated with Clinical Outcome (2021) (5)
- Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (5)
- Optical imaging of the peri-tumoral inflammatory response in breast cancer (2009) (5)
- Inflammation and matrix metalloproteinases: implications for cancer development (2004) (4)
- A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset (2016) (4)
- T H 2-polarized CD4 + T cells and macrophages limit efficacy of radiation therapy (2015) (4)
- Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma. (2019) (4)
- Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis. (2017) (3)
- Leading Edge Review The Basis of Oncoimmunology (2016) (3)
- Feasibility of real-time serial comprehensive tumor analytics: Pilot study of olaparib and durvalumab in metastatic triple negative breast cancer (mTNBC). (2020) (3)
- Multiplex immunohistochemistry for immune profiling of HPV-associated head and neck cancer (2015) (3)
- Therapeutics That Promote Sympathetic Reinnervation Modulate the Inflammatory Response After Myocardial Infarction (2022) (3)
- Abstract 3296: SMMART: Serial measurements of molecular and architectural responses to therapy (2018) (3)
- Correction: Sustained Endothelial Expression of HoxA5 In Vivo Impairs Pathological Angiogenesis And Tumor Progression (2016) (3)
- Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers (2022) (3)
- Poker face no more: cancer recurrence reveals its hand (2013) (3)
- An Integrated Clinical, Omic, and Image Atlas of an Evolving Metastatic Breast Cancer (2020) (3)
- © 2012 Landes Bioscience. Do not distribute. MR imaging of tumor-associated macrophages (2012) (3)
- Erratum: Sustained endothelial expression of HoxA5 in vivo impairs pathological angiogenesis and tumor progression (PLoS ONE (2015) 10: 3 (E0121720) DOI: 10.1371/journal.pone.0121720) (2016) (3)
- A general method for genotyping mast cell-deficient KITW/KITWυ mice by allele-specific polymerase chain reaction (1998) (2)
- Erratum: EMX2 is epigenetically silenced and suppresses growth in human lung cancer (Oncogene (2010) 29 (5969-5975) DOI: 10.1038/onc.2010.330) (2010) (2)
- Tumor progression and metastasis from genetic to microenvironmental determinants (2006) (2)
- Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach (2022) (2)
- Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma (2021) (2)
- Abstract 611: PD-1-based combination immunotherapy reinvigorates CD8+T cells in metastatic pancreatic cancer patients with improved survival (2018) (2)
- Matrix Metalloproteinases: Mediators of Tumour-Host Cell Interactions (2005) (2)
- Correction: Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma (2013) (2)
- T cell Egress via Lymphatic Vessels Limits the Intratumoral T cell Repertoire in Melanoma (2022) (2)
- HTAN Multiplex IHC Image Cytometry V0.1 v1 (2021) (2)
- CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). (2016) (2)
- Proteolytic Pathways: Intersecting Cascades in Cancer Development (2008) (2)
- Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma (2023) (1)
- T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control (2023) (1)
- Abstract 3850: Efficacy of the selective CSF-1R kinase inhibitor PLX3397 in mouse models of tumor growth and bone metastasis (2010) (1)
- Abstract 1558: Therapeutic targeting of cell surface plectin induces anti-cancer immune response and pancreatic cancer regression (2019) (1)
- Tumor Microenvironment : Study Protocols (2016) (1)
- Signaling Metastasis by Induction of Hepatocyte Growth Factor Tissue Inhibitor of Metalloproteinases-1 Promotes Liver (2007) (1)
- Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations (2020) (1)
- Abstract 4723: Macrophages foster neoplastic progression of malignant mesothelioma and limit response to chemotherapy. (2013) (1)
- Zena Werb 1945–2020 (2020) (1)
- Structural and Functional Analysis of Cell Surface Receptors with Tyrosine Kinase Activity (1986) (1)
- Abstract 3706: Validation of human and mouse myeloid panels on the NanoString® nCounter® Platform (2017) (1)
- Multiplex spatial systems analysis of local nanodose drug responses predicts effective treatment combinations of immunotherapies and targeted agents in mammary carcinoma (2021) (1)
- Sympathetic Reinnervation Alters the Inflammatory Response Following Myocardial Infarction (2021) (0)
- Table of Contents (1990) (0)
- eptor Tyrosine Kinase Signaling Favors a Protumorigenic te in Breast Cancer Cells by Inhibiting the Adaptive (2010) (0)
- Impact of the Tumor Immune Microenvironment on the Efficacy of Radiation Therapy (2011) (0)
- 87 Mesothelin-targeted immunotherapy CRS-207 plus chemotherapy as treatment for malignant pleural mesothelioma (MPM) (2016) (0)
- Table of Contents (1990) (0)
- Linkage Analysis in Familial Dysautonomia Using Variations in DNA Sequence in the β-Nerve Growth Factor Gene Region: A Beginning (1984) (0)
- Abstract 3473: High throughput screening of combination therapies to improve response to checkpoint inhibitors in solid tumors using a myelomonocytic and T cell co-culture assay (2023) (0)
- Abstract A067: Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma (2022) (0)
- Abstract 454: Targeting macrophages in a preclinical model of malignant mesothelioma (2011) (0)
- Tumor-Infiltrating Myeloid Cells in Cancer Progression and Therapy Response (2021) (0)
- A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer (2022) (0)
- The interplay between adaptive and innate immunity promotes cancer development (2004) (0)
- Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial (2021) (0)
- Abstract A28: Impact of macrophage function on the efficacy of radiation therapy (2015) (0)
- Microenvironmental regulation of lymphatic metastasis development (2004) (0)
- Abstract 4391: CD20 as a target for therapy in solid tumors (2012) (0)
- T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62 (2022) (0)
- Responses to Lung Adenocarcinoma Inhibit Endogenous Cytotoxic T Cell Tumor-Infiltrating Regulatory T Cells (2013) (0)
- carcinogenesis Cathepsin C is a tissue-specific regulator of squamous Material (2013) (0)
- High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer (2021) (0)
- mIHC staining (OHSU, Coussens' lab) SOP (TMA_TNP) v1 (2021) (0)
- BCellsRegulateMacrophagePhenotypeandResponse to Chemotherapy in Squamous Carcinomas (2014) (0)
- Abstract PL03-03: Inflammation and cancer: Repolarizing the immune microenvironment as a therapeutic anticancer strategy (2010) (0)
- Dual-modality imaging of immunofluorescence and imaging mass cytometry for whole slide imaging with accurate single-cell segmentation (2023) (0)
- Abstract C231: Colony-stimulating factor-1 receptor blockade reprograms malignant mesothelioma tumor microenvironments and decreases tumor growth. (2011) (0)
- Abstract LB-251: Manipulation of macrophage phenotype enhances the apoptotic response to chemotherapy in mesothelioma (2012) (0)
- Th1-Polarized Macrophages Enhance The Apoptotic Response To Chemotherapy In Mesothelioma (2012) (0)
- Structural features of growth factor receptors with oncogenic potential. (1986) (0)
- Utilizing Mouse Models of Human Cancer for Assessing Immune Modulation of Cancer Development (2012) (0)
- Some DCs are "B"etter. (2013) (0)
- An open protocol for modeling T Cell Clonotype repertoires using TCRβ CDR3 sequences (2022) (0)
- Antisense Oligonucleotide Targeting of Thrombopoietin Synthesis Reduces Platelet Count within the Hemostatic Range and Slows Progression of De Novo Mammary Carcinogenesis in the Mmtv-Pymt Mouse (2018) (0)
- Correction to: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer (2021) (0)
- Tumor Microenvironment Study Protocols Preface (2016) (0)
- TIMP-1-associated metastasis-promoting gene expression profile in liver-metastasis of colorectal cancer patients can explain tumor aggressiveness (2007) (0)
- Host–tumor interactions influencing cancer progression (2005) (0)
- Lab OHSU Center for Spatial Systems Biomedicine Platelet-Derived Soluble and Membrane-Bound Proteins Differentially Influence C-MYC Expression in Pancreatic Cancer Cells (2015) (0)
- Identification of a pro-metastatic microenvironment in livers of MMP-9-deficient mice. (2007) (0)
- 377 Extra-cellular Matrix Stiffness and Immune Cells Infiltrate Are Associated With Breast Tumor Phenotype (2012) (0)
- Abstract A013: Favorable changes in tumor microenvironment following intravenous dosing with live attenuatedListeria monocytogenes-based immunotherapy (2016) (0)
- Abstract 220: Intra-tumor immune heterogeneity is associated with prognosis of oropharyngeal head and neck squamous cell carcinoma (2018) (0)
- Inflammation and Cancer: Organ-specific Regulation of Cancer Development (2008) (0)
- Cancer Microenvironments as Therapeutic Targets (2014) (0)
- CMR2009: 10.01: Imaging tumor necrosis with the second-generation, folate-specific ultrasmall paramagnetic iron oxide (USPIO) P1133 with magnetic resonance (MR) imaging in a transgenic mouse model for breast cancer (2009) (0)
- A Web-based Software Resource for Interactive Analysis of Multiplex Tissue Imaging Datasets (2022) (0)
- PL2-1: Macrophages as Novel Targets for Therapy in Breast Cancer. (2011) (0)
- 39 Spatial single-cell quantitative analyses of human head and neck squamous cell carcinomas (2020) (0)
- Abstract A03: Relieving immune suppressive pathways in breast cancer to improve outcomes (2020) (0)
- 515 CRS-207, a mesothelin-targeted immunotherapy, in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM) (2015) (0)
- Complement C 5 a Fosters S quamousCarcinogenesis and Limits T Cell Response to Chemotherapy Graphical (2018) (0)
- 14th Pezcoller Symposium: The Novel Dichotomy of Immune Interactions with Tumors 30 May–1 June 2002, Trento, Italy (2002) (0)
- Abstract A21: Characterization of the immune environment in the in situ to invasive breast carcinoma transition (2018) (0)
- Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. (2009) (0)
- Abstract I03: Immune contexture of human pancreatic cancer (2019) (0)
- Author Correction: T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control (2023) (0)
- Extravasation and stromal cell uptake of fluorescent dextran in tumors. (2010) (0)
- Macrophages in tumour development and metastasis (2008) (0)
- Ultrastructure of immunogenic cell death in vivo (2021) (0)
- Abstract 3844: Targeting macrophages as a novel therapeutic approach for malignant pleural mesothelioma (2010) (0)
- Total Thyroidectomy Costs and Outcomes vary Regionally: A national Analysis of Pediatric (2022) (0)
- Abstract 489: Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development. (2013) (0)
- Abstract 2840: Efficacy of radiation therapy in mammary carcinomas is regulated by macrophages (2011) (0)
- Abstract 880: MYC drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma (2022) (0)
- Correction to: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer (2021) (0)
- Abstract 4491: Association of intratumoral immunologic profile with overall survival in metastatic pancreatic cancer patients treated with combination immunotherapy with or without PD-1 blockade (2019) (0)
- Systematic identification of synergistic combinations of targeted agents and immunotherapies in breast cancer using intratumor multiplex implantable microdevice assay (2021) (0)
- Challenges and opportunities for modeling aging and cancer. (2023) (0)
- Abstract PO-061: Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma (2021) (0)
- Novel Therapeutics Modulate Cardiac Leukocyte Populations Following Myocardial Infarction (2022) (0)
- Abstract #5669: Immune-regulation of non-small cell lung cancer development (2009) (0)
- Inflammation and cancer: new targets for therapy in cancer (2019) (0)
- Imaging , Diagnosis , Prognosis MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles (2011) (0)
- Abstract BL1: Modeling Immune Response: Lessons Learned from Mouse Models of Cancer Development (2019) (0)
- Abstract 4916: Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer (2023) (0)
- Supervised learning of high-confidence phenotypic subpopulations from single-cell data (2023) (0)
- Abstract PR11: Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer (2020) (0)
- Abstract A15: Immune-related changes in breast cancer tumor evolution (2018) (0)
- Activation vs. Organization: Prognostic Implications of T and B Cell Features of the PDAC Microenvironment (2020) (0)
- Abstract 2698: Transcriptional profiling of human TAMs highlights differences in breast and endometrial tumour microenvironments (2016) (0)
- Abstract A17: An integrin agonist suppresses breast cancer by reducing CD11b+ leukocytes, promoting anti-tumor immunity (2016) (0)
- Abstract A098: A role for fibrosis in promoting pro-tumor immune response in breast cancer (2016) (0)
- Molecular Features Involved in Cell Surface Receptor Function and Their Role in Oncogenesis (1987) (0)
- Abstract 2703: Leukocyte complexity in human breast cancer and response to chemotherapy (2011) (0)
- Wild-type FVB/N mice are unusually susceptible to Mycoplasma pulmonis respiratory tract infection (1998) (0)
- Q&A: Lisa Coussens on immune reprogramming. (2012) (0)
- Abstract B118: Developing a molecular and cellular atlas of pancreatic disease (2015) (0)
- Abstract IA26: Dynamic interactions between myeloid and lymphoid cells regulate response to therapy in solid tumors (2020) (0)
- Abstract 2301: Myeloid cells promote fibroblast invasion and lead mammary adenocarcinoma cell invasion. (2013) (0)
- Understanding the tumor immune microenvironment (TIME) for effective therapy (2018) (0)
- 139 Complement C5a regulates squamous carcinogenesis (2017) (0)
- Abstract 3247: Combination therapy using PERK and PD1/PD-L1 inhibitors reprograms tumor associated macrophages and reduces tumor burden (2023) (0)
- Abstract 2149: Biomarker-driven selection of polyADP ribose polymerase inhibitors (PARPi)-based combination therapies in patients with metastatic triple negative breast cancer (mTNBC) (2022) (0)
- Alignment, Segmentation and Neighborhood Analysis in Cyclic Immunohistochemistry Data Using CASSATT (2022) (0)
- Cancer esearch oenvironment and Immunology eptor Tyrosine Kinase Signaling Favors a Protumorigenic te in Breast Cancer Cells by Inhibiting the Adaptive R une Response (2010) (0)
- Immune Enhancement of Skin Carcinogenesis by CD4 (cid:2) T Cells (2003) (0)
- Abstract 4949: Combined immunochemotherapy for poor prognosis breast cancer. (2013) (0)
- TIM-3 Regulates CD 103 + D endritic Cell Function and Response to Chemotherapy in Breast Cancer Graphical (2018) (0)
- Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models (2018) (0)
- SESSION 2: INFLAMMATION (2004) (0)
- Microenvironmental Regulation of Mammary Carcinogenesis (2008) (0)
- The early detection of cancer. (1966) (0)
- Abstract 3862: Defining immune contexture in small cell lung cancer: Implications for immunotherapy (2020) (0)
- Abstract P5-13-05: Multiplex spatial systems analysis of responses to spatially separate nanoliter doses of drug predicts systemic immune-modulating combination treatments in breast cancer (2022) (0)
- Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study (2022) (0)
- Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs. (2021) (0)
This paper list is powered by the following services:
Other Resources About Lisa Coussens
What Schools Are Affiliated With Lisa Coussens?
Lisa Coussens is affiliated with the following schools:
